spacer
home > ict > winter 2021 > data collection during the covid-19 pandemic and beyond
PUBLICATIONS
International Clinical Trials

Data Collection During the COVID-19 Pandemic and Beyond


As we all know, data are always at the centre of the clinical development process. Researchers have always looked at collecting varieties of data from patients to assess safety and efficacy of the new medications in trials, and technology has been of great help in the last decade enabling the seamless flow of data from various sources. However, the basic structure of clinical trials has not changed drastically, with the majority of patient and monitoring visits performed in traditional ways where patients and monitors travel to investigator sites.

As the COVID-19 pandemic took hold last year, major CROs reported 70-80% of their sites becoming inaccessible or non-functional due to travel limitations for both patients and monitors, and also because of the decrease in available health workers in hospitals to support research. Many clinical trials have been put on hold and new trials postponed due to the global crisis, however, itís promising to see many have implemented virtual trial models or hybrid models to start or continue the research in these unprecedented times. This is a very positive move, and inspiring for the larger industry to contemplate how virtual models could improve patient participation and their experience of clinical trials. Here are some areas for consideration when taking a decentralised approach to conducting clinical trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Deepu Joseph is currently serving as Vice President and Global Head of Clinical Data Management with Quanticate and has over 16 years of experience in managing and driving clinical data management operations delivery across major CROs.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera reinforces its value proposition with a refreshing visual identity

At Nemera, we have been successfully providing high quality drug delivery device solutions to our customers and patients for years. We design and manufacture devices with the ultimate goal to improve patient outcomes and experience.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement